At the news
? NEUTRALIMPACT 4/10 8-K filed Nov 9, 2026 at 08:34 ET
Vistagen announced FDA feedback from a Type C meeting for its lead candidate fasedienol in social anxiety disorder. The FDA provided constructive guidance on using the LSAS as a primary endpoint in a future Phase 3 study and recognized fasedienol's safety profile. The company plans to submit a revised protocol and pursue development for the overall treatment of SAD, but no financial data, trial results, or approval timeline were disclosed.
- Vistagen held a Type C meeting with the FDA regarding fasedienol for social anxiety disorder (SAD).
- FDA provided constructive feedback on using the Liebowitz Social Anxiety Scale (LSAS) as the primary endpoint in a future Phase 3 study.
- FDA recommended interim assessments using eDiaries and qualitative patient surveys to evaluate acute and longer-term effects.
- FDA recognized fasedienol's reported safety profile and potential to benefit a broad SAD population.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access